Skip to main content
Journal of General Internal Medicine logoLink to Journal of General Internal Medicine
. 2013 Aug 14;29(1):248–249. doi: 10.1007/s11606-013-2560-8

Warfarin-Induced Skin Necrosis

Natalia Kozac 1,2, Ami Schattner 1,2,✉
PMCID: PMC3889929  PMID: 23943419

A 78-year-old, obese woman with hypertension and atrial fibrillation stopped long-term warfarin for one week due to an asymptomatic international normalized ratio (INR) of 8.6. Three days after resuming warfarin, painful skin lesions developed on her lower extremities (Fig. 1a and b). Her INR was 2.5 at the time. Warfarin-induced skin necrosis (WISN) was diagnosed and warfarin was replaced by low molecular weight heparin (LMWH). The lesions stabilized and slowly resolved over 4 weeks.

Figure 1.

Figure 1.

a and b: The patient’s lesions on admission, showing coalescing ecchymoses on both legs and multiple hemorrhagic bullae, some replaced by black necrotic skin ulcers.

Paradoxical thrombosis following warfarin is a serious, but rare adverse event (≤ 0.1 % of treated patients).1 Diffuse microthrombi occur within subcutaneous capillaries and venules, damaging endothelial cells, and leading to red blood cell extravasation and skin necrosis.

WISN is diagnosed by the history, typical lesions on exam, and exclusion of alternative diagnoses.2 It occurs primarily in obese women. Risk factors include recent initiation of warfarin (average 3–6 days), high “loading” doses of warfarin, and hereditary protein C or S deficiency.3,4 These risk factors were absent in this case. Prompt recognition and drug withdrawal may improve prognosis.5 LMWH bridging is important and the use of the newer anticoagulants may be considered, although safety data is lacking. Resumption of warfarin remains a controversial topic.6

Acknowledgments

Conflict of Interest

The authors declare that they do not have a conflict of interest.

Footnotes

Kozak Natalia and Schattner Ami had access to the data and a role in writing the manuscript.

REFERENCES

  • 1.Chan YC, Valenti D, Mansfield AO, et al. Warfarin induced skin necrosis. Br J Surg. 2000;87:266–272. doi: 10.1046/j.1365-2168.2000.01352.x. [DOI] [PubMed] [Google Scholar]
  • 2.Nazarian RM, Van Cott EM, Zembowicz A, et al. Warfarin-induced skin necrosis. J Am Acad Dermatol. 2009;61:325–332. doi: 10.1016/j.jaad.2008.12.039. [DOI] [PubMed] [Google Scholar]
  • 3.Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272–1285. doi: 10.1056/NEJM199411103311906. [DOI] [PubMed] [Google Scholar]
  • 4.Essex DW, Wynn SS, Jin DK. Late-onset warfarin-induced skin necrosis: case report and review of the literature. Am J Hematol. 1998;57:233–237. doi: 10.1002/(SICI)1096-8652(199803)57:3<233::AID-AJH10>3.0.CO;2-B. [DOI] [PubMed] [Google Scholar]
  • 5.Miura Y, Ardenghy M, Ramasastry S, Kovach R, Hochberg J. Coumadin necrosis of the skin: report of four cases. Ann Plast Surg. 1996;37:332–337. doi: 10.1097/00000637-199609000-00017. [DOI] [PubMed] [Google Scholar]
  • 6.Jillella AP, Lutcher CL. Reinstituting warfarin in patients who develop warfarin skin necrosis. Am J Hematol. 1996;52:117–119. doi: 10.1002/(SICI)1096-8652(199606)52:2<117::AID-AJH9>3.0.CO;2-X. [DOI] [PubMed] [Google Scholar]

Articles from Journal of General Internal Medicine are provided here courtesy of Society of General Internal Medicine

RESOURCES